These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34555844)

  • 21. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
    Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
    Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
    Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
    Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
    Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
    Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
    An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
    Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
    Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
    Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
    Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
    Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
    Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells.
    Iversen PO; Hart PH; Bonder CS; Lopez AF
    Cancer Res; 1997 Feb; 57(3):476-80. PubMed ID: 9012477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML).
    Privitera E; Longoni D; Brambillasca F; Biondi A
    Leukemia; 1997 Dec; 11(12):2045-8. PubMed ID: 9447818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.
    Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M
    Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
    Grockowiak E; Korn C; Rak J; Lysenko V; Hallou A; Panvini FM; Williams M; Fielding C; Fang Z; Khatib-Massalha E; García-García A; Li J; Khorshed RA; González-Antón S; Baxter EJ; Kusumbe A; Wilkins BS; Green A; Simons BD; Harrison CN; Green AR; Lo Celso C; Theocharides APA; Méndez-Ferrer S
    Nat Cancer; 2023 Aug; 4(8):1193-1209. PubMed ID: 37550517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
    Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
    Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
    Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.